Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
(2009) In Haemophilia 15. p.41343-41343- Abstract
- Summary. The bypassing agents factor eight inhibitor bypassing activity (FEIBA) anti-inhibitor coagulant complex and recombinant activated factor VII (rFVIIa) have been established as safe and effective therapies for treating bleeding episodes in haemophilia patients with inhibitors. However, the efficacy of each bypassing agent can vary, and neither agent is universally effective. The reasons for such variability have yet to be confirmed, but may involve patient-specific factors and the mechanisms of action (MOAs) and pharmacokinetic profiles of these two agents. This issue underscores the necessity of both products in the comprehensive care of patients with haemophilia and inhibitors. The objective of this review is to discuss the... (More)
- Summary. The bypassing agents factor eight inhibitor bypassing activity (FEIBA) anti-inhibitor coagulant complex and recombinant activated factor VII (rFVIIa) have been established as safe and effective therapies for treating bleeding episodes in haemophilia patients with inhibitors. However, the efficacy of each bypassing agent can vary, and neither agent is universally effective. The reasons for such variability have yet to be confirmed, but may involve patient-specific factors and the mechanisms of action (MOAs) and pharmacokinetic profiles of these two agents. This issue underscores the necessity of both products in the comprehensive care of patients with haemophilia and inhibitors. The objective of this review is to discuss the evidence of a differential haemostatic response to bypassing agents and the potential roles of MOA and patient-specific factors in contributing to the differences in response. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1271370
- author
- Berntorp, Erik LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Haemophilia
- volume
- 15
- pages
- 41343 - 41343
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000262470600002
- pmid:19016901
- scopus:63049090494
- pmid:19016901
- ISSN
- 1351-8216
- DOI
- 10.1111/j.1365-2516.2008.01931.x
- language
- English
- LU publication?
- yes
- id
- 226c587f-8a14-49d9-84c5-89248fda581e (old id 1271370)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19016901?dopt=Abstract
- date added to LUP
- 2016-04-04 08:56:54
- date last changed
- 2022-08-15 22:01:27
@article{226c587f-8a14-49d9-84c5-89248fda581e,
abstract = {{Summary. The bypassing agents factor eight inhibitor bypassing activity (FEIBA) anti-inhibitor coagulant complex and recombinant activated factor VII (rFVIIa) have been established as safe and effective therapies for treating bleeding episodes in haemophilia patients with inhibitors. However, the efficacy of each bypassing agent can vary, and neither agent is universally effective. The reasons for such variability have yet to be confirmed, but may involve patient-specific factors and the mechanisms of action (MOAs) and pharmacokinetic profiles of these two agents. This issue underscores the necessity of both products in the comprehensive care of patients with haemophilia and inhibitors. The objective of this review is to discuss the evidence of a differential haemostatic response to bypassing agents and the potential roles of MOA and patient-specific factors in contributing to the differences in response.}},
author = {{Berntorp, Erik}},
issn = {{1351-8216}},
language = {{eng}},
pages = {{41343--41343}},
publisher = {{Wiley-Blackwell}},
series = {{Haemophilia}},
title = {{Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.}},
url = {{http://dx.doi.org/10.1111/j.1365-2516.2008.01931.x}},
doi = {{10.1111/j.1365-2516.2008.01931.x}},
volume = {{15}},
year = {{2009}},
}